Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Cash: 2014-2024

Historic Change in Cash for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $136.0 million.

  • Cartesian Therapeutics' Change in Cash fell 112.84% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.7 million, marking a year-over-year decrease of 154.15%. This contributed to the annual value of $136.0 million for FY2024, which is 557.11% up from last year.
  • Cartesian Therapeutics' Change in Cash amounted to $136.0 million in FY2024, which was up 557.11% from -$29.8 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Change in Cash ranged from a high of $136.0 million in FY2024 and a low of -$29.8 million during FY2023.
  • In the last 3 years, Cartesian Therapeutics' Change in Cash had a median value of -$7.4 million in 2022 and averaged $32.9 million.
  • In the last 5 years, Cartesian Therapeutics' Change in Cash slumped by 302.14% in 2023 and then skyrocketed by 557.11% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Change in Cash (Yearly) stood at $48.5 million in 2020, then slumped by 150.77% to -$24.6 million in 2021, then surged by 69.96% to -$7.4 million in 2022, then crashed by 302.14% to -$29.8 million in 2023, then spiked by 557.11% to $136.0 million in 2024.